Preventing Cardiovascular Disease in Patients with Diabetes: Use of Aspirin for Primary Prevention

Published on Feb 13, 2015in Current Cardiology Reports2.434
· DOI :10.1007/S11886-015-0566-Z
Dhaval Desai1
Estimated H-index: 1
(Johns Hopkins University),
Haitham M. Ahmed18
Estimated H-index: 18
(Johns Hopkins University),
Erin D. Michos61
Estimated H-index: 61
(Johns Hopkins University)
Diabetics are at high risk for atherosclerotic cardiovascular disease (ASCVD) and are considered a coronary heart disease risk equivalent. The utility of aspirin in primary prevention of ASCVD in diabetic patients has been widely studied and is still debated. Overall, the current evidence suggests a modest benefit for reduction in ASCVD events with the greatest benefit among those with higher baseline risk, but at the cost of increased risk of gastrointestinal bleeding. Diabetic patients at higher risk (with 10-year ASCVD risk >10 %) are generally recommended for aspirin therapy if bleeding risk is felt to be low. A patient-provider discussion is recommended before prescribing aspirin therapy. Novel markers such as coronary artery calcium scores and high-sensitivity C-reactive protein may help refine ASCVD risk prediction and guide utility for aspirin therapy. This article will review the literature for the most up-to-date studies evaluating aspirin therapy for primary prevention of ASCVD in patients with diabetes.
📖 Papers frequently viewed together
2 Citations
1 Citations
9 Citations
#1Jiang HeH-Index: 109
#2Paul K. WheltonH-Index: 121
Last. Michael J. KlagH-Index: 95
view all 4 authors...
Context.— Aspirin has been widely used to prevent myocardial infarction and ischemic stroke but some studies have suggested it increases risk of hemorrhagic stroke. Objective.— To estimate the risk of hemorrhagic stroke associated with aspirin treatment. Data Sources.— Studies were retrieved using MEDLINE (search terms, aspirin, cerebrovascular disorders, and stroke), bibliographies of the articles retrieved, and the authors’ reference files. Study Selection.— All trials published in English-lan...
469 Citations
#1F. GeraldH-Index: 2
#2R. FowkesH-Index: 2
Last. Gordon D. MurrayH-Index: 112
view all 10 authors...
2 Citations
#1Yasuo Ikeda (Waseda University)H-Index: 29
#2Kazuyuki ShimadaH-Index: 74
Last. Naoki IshizukaH-Index: 20
view all 11 authors...
the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.190.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P =. 02) and transient ...
196 CitationsSource
#1Manling Xie (HUST: Huazhong University of Science and Technology)H-Index: 5
#2Zhilei Shan (HUST: Huazhong University of Science and Technology)H-Index: 19
Last. Liegang Liu (HUST: Huazhong University of Science and Technology)H-Index: 52
view all 10 authors...
Objective To evaluate the benefits and harms of aspirin for the primary prevention of CVD and determine whether the effects vary by sex and diabetes status. Methods We searched Medline, Embase, and Cochrane databases for randomized controlled trials comparing the effects of aspirin with placebo or control in people with no pre-existing CVD. Two investigators independently extracted data and assessed the study quality. Analyses were performed using Stata version 12. Results Fourteen trials (107,6...
51 CitationsSource
#1Sigrun Halvorsen (Oslo University Hospital)H-Index: 34
#2Felicita Andreotti (CUA: The Catholic University of America)H-Index: 68
Last. Raffaele De CaterinaH-Index: 90
view all 9 authors...
Although the use of oral anticoagulants (vitamin K antagonists) has been abandoned in primary cardiovascular prevention due to lack of a favorable benefit-to-risk ratio, the indications for aspirin use in this setting continue to be a source of major debate, with major international guidelines providing conflicting recommendations. Here, we review the evidence in favor and against aspirin therapy in primary prevention based on the evidence accumulated so far, including recent data linking aspiri...
125 CitationsSource
#1Michael D. Miedema (Harvard University)H-Index: 22
#2Daniel A. Duprez (UMN: University of Minnesota)H-Index: 23
Last. Aaron R. Folsom (UMN: University of Minnesota)H-Index: 206
view all 10 authors...
Background—Aspirin for the primary prevention of coronary heart disease (CHD) is only recommended for individuals at high risk for CHD although the majority of CHD events occur in individuals who are at low to intermediate risk. Methods and Results—To estimate the potential of coronary artery calcium (CAC) scoring to guide aspirin use for primary prevention of CHD, we studied 4229 participants from the Multi-Ethnic Study of Atherosclerosis who were not on aspirin at baseline and were free of dia...
125 CitationsSource
#1Hirofumi Soejima (Kumamoto University)H-Index: 34
#2Hisao OgawaH-Index: 114
Last. Yoshihiko Saito (Nara Medical University)H-Index: 98
view all 13 authors...
Abstract Background and purpose There are few data that demonstrate a significant effect of aspirin therapy for diabetic patients as primary prevention for cardiovascular events. A guideline recommends the use of aspirin as a primary prevention strategy in patients with diabetes who are at increased cardiovascular risk including those who have additional risk factors. To clarify the effect of primary prevention with aspirin therapy on diabetic patients, the relationship between C-reactive protei...
12 CitationsSource
#1M. Piepoli (LNU: Linnaeus University)H-Index: 18
#2Arno W. HoesH-Index: 103
Last. W. M. Monique Verschuren (European Society of Cardiology)H-Index: 64
view all 26 authors...
ABI : ankle–brachial index ACCORD : Action to Control Cardiovascular Risk in Diabetes ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation AGREE : Appraisal of Guidelines Research and Evaluation AHA : American Heart Association apoA1 : apolipoprotein A1 apoB : apolipoprotein B CABG : coronary artery bypass graft surgery CARDS : Collaborative AtoRvastatin Diabetes Study CCNAP : Council on Cardiovascular Nursing and Allied Professions CHA...
6,730 CitationsSource
#1Hirofumi Soejima (Kumamoto University)H-Index: 34
#2Hisao Ogawa (Kumamoto University)H-Index: 114
Last. Yoshihiko Saito (Nara Medical University)H-Index: 98
view all 13 authors...
Background: There are few data that demonstrate a significant effect of aspirin therapy for diabetic patients. To clarify the effect of the primary prevention of aspirin therapy in diabetic patients, the relationship between blood pressure (BP) and the incidence of atherosclerotic events was investigated in participants in the Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial. Methods and Results: We divided the JPAD participants according to their systolic (S...
15 CitationsSource
#1Nathan D. Wong (UCI: University of California, Irvine)H-Index: 102
#2Jennifer C. Nelson (UW: University of Washington)H-Index: 41
Last. Robert Detrano (UCI: University of California, Irvine)H-Index: 82
view all 14 authors...
Objectives This study sought to examine and compare the incidence and progression of coronary artery calcium (CAC) among persons with metabolic syndrome (MetS) and diabetes mellitus (DM) versus those with neither condition. Background MetS and DM are associated with subclinical atherosclerosis as evidenced by CAC. Methods The MESA (Multiethnic Study of Atherosclerosis) included 6,814 African American, Asian, Caucasian, and Hispanic adults 45 to 84 years of age, who were free of cardiovascular di...
115 CitationsSource
Cited By3
#1Bo Qu (CDUTCM: Chengdu University of Traditional Chinese Medicine)H-Index: 1
#2Yuhua He (CDUTCM: Chengdu University of Traditional Chinese Medicine)H-Index: 1
Last. Mingquan Li (CDUTCM: Chengdu University of Traditional Chinese Medicine)H-Index: 4
view all 6 authors...
Purpose To perform a systematic review and meta-analysis to evaluate the cardiovascular prevention effect of aspirin among patients with chronic kidney disease (CKD).
2 CitationsSource
#1Marian Goicoechea (Hospital General Universitario Gregorio Marañón)H-Index: 24
#2Soledad García de Vinuesa (Hospital General Universitario Gregorio Marañón)H-Index: 13
Last. José Luño (Hospital General Universitario Gregorio Marañón)H-Index: 26
view all 15 authors...
Background Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular events. However, limited evidence is available regarding the use of aspirin in CKD patients to decrease cardiovascular risk and to slow renal disease progression.
18 CitationsSource
#1Carmen LambertH-Index: 3
#2Judit Cubedo (ISCIII: Carlos III Health Institute)H-Index: 15
Last. Lina Badimon (ISCIII: Carlos III Health Institute)H-Index: 99
view all 8 authors...
Background: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events. The ingestion of high-glycemic index (GI) diets, specially sweetened beverage consumption, has been associated with the development of T2DM and CV disease. Objective: We investigated the effects of the intake of a sweetened beverage, obtained from natural carbohydrates containing pinitol (PEB) compared to a sucrose-enriched beverage (SEB) in the context of impaired glucose tolerance (...
8 CitationsSource